Invention Grant
US09434734B2 Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
有权
取代的吡唑并喹唑啉酮和吡咯并喹唑啉酮作为组II代谢型谷氨酸受体的变构调节剂
- Patent Title: Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
- Patent Title (中): 取代的吡唑并喹唑啉酮和吡咯并喹唑啉酮作为组II代谢型谷氨酸受体的变构调节剂
-
Application No.: US14403070Application Date: 2013-05-21
-
Publication No.: US09434734B2Publication Date: 2016-09-06
- Inventor: Stanislas Mayer , Stephan Schann
- Applicant: Domain Therapeutics
- Applicant Address: FR Illkirch-Graffenstaden
- Assignee: DOMAIN THERAPEUTICS
- Current Assignee: DOMAIN THERAPEUTICS
- Current Assignee Address: FR Illkirch-Graffenstaden
- Agency: Buchanan Ingersoll & Rooney PC
- Priority: EP12360043 20120521
- International Application: PCT/EP2013/060426 WO 20130521
- International Announcement: WO2013/174822 WO 20131128
- Main IPC: C07D487/04
- IPC: C07D487/04 ; G01N33/566 ; G01N33/94
Abstract:
The present invention relates to the pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I), as well as pharmaceutical compositions containing them, and their use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals, in particular their use in the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders.
Public/Granted literature
Information query
